Pallas Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Pallas Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$731K	Sell	1,638 -2,603	-61%	-$1.21M	0.03%	405
2025 Q4	$1.92M	Buy	4,241 +1,353	+47%	+$583K	0.06%	229
2025 Q3	$1.13M	Sell	2,888 -171	-6%	-$71.5K	0.04%	319
2025 Q2	$1.36M	Buy	3,059 +579	+23%	+$267K	0.05%	261
2025 Q1	$1.2M	Buy	2,480 +19	+0.8%	+$8.85K	0.05%	267
2024 Q4	$991K	Buy	2,461 +75	+3%	+$34.8K	0.04%	234
2024 Q3	$1.13M	Sell	2,386 -5	-0.2%	-$2.4K	0.05%	206
2024 Q2	$1.17M	Buy	2,391 +1,673	+233%	+$726K	0.05%	195
2024 Q1	$300K	Buy	718 +128	+22%	+$54.1K	0.01%	359
2023 Q4	$240K	Sell	590 -61	-9%	-$22.5K	0.01%	336
2023 Q3	$233K	Buy	651 +14	+2%	+$4.9K	0.01%	316
2023 Q2	$228K	Buy	+637	New	+$215K	0.01%	242
2021 Q4	–	Sell	-1,247	Closed	-$236K	–	406
2021 Q3	$236K	Sell	1,247 -8,803	-88%	-$1.72M	0.03%	340
2021 Q2	$2.01M	Buy	10,050 +1,657	+20%	+$347K	0.28%	70
2021 Q1	$1.79M	Buy	+8,393	New	+$1.84M	0.4%	52

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Pallas Capital Advisors's VRTX Position: Q1 2026 in Review

Pallas Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 61% in Q1 2026, selling an estimated $1.21M and leaving 1,638 shares worth $731K. The position accounts for 0.03% of the portfolio, ranked #405.

Pallas Capital Advisors first reported a position in VRTX in Q1 2021 and has held it in 15 quarters since. The position peaked at $2.01M in Q2 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Pallas Capital Advisors held 1,638 shares of Vertex Pharmaceuticals worth $731K as of Q1 2026.
Pallas Capital Advisors sold 2,603 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.21M.
Vertex Pharmaceuticals made up 0.03% of Pallas Capital Advisors's portfolio in Q1 2026, its #405 holding.
Pallas Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 15 quarters since.
Pallas Capital Advisors's Vertex Pharmaceuticals position peaked at $2.01M in Q2 2021.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.